MedTrace Logo

VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma

NCT02718443 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2018-10-19

No results posted yet for this study

Summary

VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01

Conditions

Interventions

DRUG

VXM01

Oral immunotherapy targeting VEGFR2

Sponsors & Collaborators

  • Vaximm GmbH

    lead INDUSTRY

Principal Investigators

  • Wolfgang Wick, MD · Neurology Clinic and National Center for Tumor Diseases

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-08-31
Completion
2018-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02718443 on ClinicalTrials.gov